ArticleDiabetologia2004
Loss of beta cell function as fasting glucose increases in the non-diabetic range.
Article in Diabetologia, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes
A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation
Who cites it
50 citing papers in PubMed, 130 citations in OpenAlex.
- Beneficial Effects of Carbohydrate Restriction in Type 2 Diabetes Can Be Traced to Changes in Hepatic Metabolism.The Journal of clinical endocrinology and metabolism · 2025Trial
- Pancreaticoduodenectomy model demonstrates a fundamental role of dysfunctional β cells in predicting diabetes.The Journal of clinical investigation · 2021Trial
- Favourable metabolic effects of a eucaloric lower-carbohydrate diet in women with PCOS.Clinical endocrinology · 2013Trial
- Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment.Diabetes technology & therapeutics · 2012Trial
- Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes.Diabetes care · 2011Trial
- Glucodensity functional profiles outperform traditional continuous glucose monitoring metrics.Scientific reports · 2025Article
- The importance of intravenous glucose tolerance test glucose stimulus for the evaluation of insulin secretion.Scientific reports · 2024Article
- β Cell Stress and Endocrine Function During T1D: What Is Next to Discover?Endocrinology · 2023Article
- Hexokinase-linked glycolytic overload and unscheduled glycolysis in hyperglycemia-induced pathogenesis of insulin resistance, beta-cell glucotoxicity, and diabetic vascular complications.Frontiers in endocrinology · 2023Article
- The β-cell glucose toxicity hypothesis: Attractive but difficult to prove.Metabolism: clinical and experimental · 2021Review
- A Narrative Review of Human Clinical Trials on the Impact of Phenolic-Rich Plant Extracts on Prediabetes and Its Subgroups.Nutrients · 2021Review
- Article
- Metformin Preserves β-Cell Compensation in Insulin Secretion and Mass Expansion in Prediabetic Nile Rats.International journal of molecular sciences · 2021Article
- Observational
- A longitudinal big data approach for precision health.Nature medicine · 2019Article
- Postprandial Reactive Hypoglycemia.Sisli Etfal Hastanesi tip bulteni · 2019Review
- Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus.Clinical pharmacology : advances and applications · 2019Review
- Fasting Plasma Glucose Indicates Reversibility of the Acute Insulin Response after Short-Term Intensive Insulin Therapy in Patients with Various Duration of Type 2 Diabetes.Journal of diabetes research · 2018Article
- Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose.Diabetes · 2017 · on this mapArticle
- Exercise resistance across the prediabetes phenotypes: Impact on insulin sensitivity and substrate metabolism.Reviews in endocrine & metabolic disorders · 2016Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisOur aim was to define the level of glycaemia at which pancreatic insulin secretion, particularly first-phase insulin release, begins to decline.
methodsPlasma glucose and insulin concentrations were measured during an IVGTT in 553 men with non-diabetic fasting plasma glucose concentrations. In 466 of the men C-peptide was also estimated. IVGTT insulin secretion in first and late phases was assessed by: (i) the circulating insulin response; (ii) population parameter deconvolution analysis of plasma C-peptide concentrations; and (iii) a combined model utilising both insulin and C-peptide concentrations. Measurements of insulin sensitivity and elimination were also derived by modelling analysis.
resultsAs fasting plasma glucose (FPG) increased, IVGTT first-phase insulin secretion declined by 73%, 71% and 68% for the three methods respectively. The FPG values at which this decline began, determined by change point regression, were 4.97, 5.16 and 5.42 mmol/l respectively. The sensitivity of late-phase insulin secretion to glucose declined at FPG concentrations above 6.0 mmol/l. Insulin elimination, but not insulin sensitivity, varied with FPG. CONCLUSIONS/
interpretationThe range of FPG over which progressive loss of the first-phase response begins may be as low as 5.0 to 5.4 mmol/l, with late-phase insulin responses declining at FPG concentrations above 6.0 mmol/l.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.